AdvaMed President and CEO Scott Whitaker testified before the U.S. Senate Finance Committee, bringing attention to the pressing issue of how tariffs could impact the medtech industry and, most importantly, the patients who depend on it. 

The message resonated across the health care ecosystem: Medtech is not optional. It’s essential. Tariff policies that fail to account for this reality could jeopardize access to life-saving care. Industry leaders from across the country expressed strong support for AdvaMed’s leadership and advocacy:

“Scott Whitaker’s testimony before the U.S. Senate Committee on Finance on the impact of tariffs on U.S. supply chains is an important moment for AdvaMed and our industry to drive a deeper understanding of the critical role medical technology organizations have in the care of patients, as well as our significant economic impact across the U.S. GE HealthCare operates at the center of the U.S. healthcare ecosystem, delivering innovation through precision care, digitizing healthcare, driving productivity, and improving outcomes for patients, providers, health systems, and researchers around the world.”
— Peter J. Arduini, President and CEO, GE HealthCare

“At Zimmer Biomet our mission is to alleviate pain and improve the quality of life for people around the world. This mission drives us to innovate boldly and operate with agility, ensuring that patients receive the care they need, when and where they need it. Scott’s testimony this week underscores the urgency of safeguarding our industry’s ability to deliver essential, life-saving innovations without disruption.”

“I’m proud to stand alongside AdvaMed and many others working every day to advance healthcare and improve patients’ lives. And yes….I do believe that logic will prevail on this one!”
— Ivan Tornos, President and Chief Executive Officer, Zimmer Biomet

“Thank you Scott Whitaker and AdvaMed for your advocacy on behalf of the entire MedTech industry and maintaining laser focus on the providers and patients we all so passionately serve.”
— Heather Knight, Chief Operating Officer, Baxter International

“Thank you, Scott Whitaker and the AdvaMed team, for your advocacy on behalf of the medtech industry. We at LifeSciencesNY, our members, supporters and host communities across the Empire State benefit from your hard work and voice on our behalf.”
— Winthrop Thurlow, Executive Director at LifeSciencesNY

“Great job!! Thank you for being the voice to the industry.”
— Trevor Theriot, Co-Founder and CEO/President of ManaMed

“HINJ applauds you, Scott Whitaker and your entire AdvaMed team – thank you for your advocacy efforts and for being such a strong voice for our industry.”
— HealthCare Institute of New Jersey (HINJ)

“It takes real leadership and courage to speak up about this… Thank you for representing MedTech, HealthTech, and the millions of patients who rely on timely, effective care — and their clinicians providing it.”
— David Cole, Chief Strategy Officer at PROXDIS

“Scott… thank you for your leadership and AdvaMed’s advocacy.”
– Lee Grossman, Chief Executive Officer at Orthopaedic Research and Education Foundation

“We have been delivering life-saving technologies to the U.S. from the UK for over 20 years, and fully endorse a tariff exemption for life-saving medical devices.”
– Russ Mably, CEO of CELOX Medical

“Yes, let’s do this. Go Scott Whitaker, AdvaMed”
– Tom Salemi, Editorial Director, DeviceTalks WTWH Media LLC

The medtech community is firm in its view: These products are essential, and the policies that govern them must reflect that. AdvaMed will continue working with the Administration and Congress to ensure tariff policy supports medtech innovation and access to lifesaving medtech for all patients. You can find a resource dedicated to navigating tariffs and AdvaMed’s Rapid Response here.